Form 4: Akero Therapeutics CSO Sells Shares for Tax Obligations

Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, sold 553 shares of common stock at $43.02 per share to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, Inc. (AKRO), reported a sale of common stock.
• The transaction involved 553 shares of common stock.
• The shares were sold at a price of $43.02 per share.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• This "sell-to-cover" transaction was automatic and not at the discretion of Mr. Rolph, as per the issuer's policy.
• Following this transaction, Mr. Rolph beneficially owns 166,571 shares of common stock directly.
• The transaction date is reported as September 11, 2025, and was made pursuant to a Rule 10b5-1 plan.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary 'sell-to-cover' for tax purposes, indicating a neutral sentiment as it does not reflect a change in investment outlook by the insider.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

This Form 4 filing reports a routine insider transaction for tax purposes, which is common across all industries when restricted stock units vest. It does not provide information relevant to broader industry trends or competitive landscape.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it represents a small, non-discretionary sale for tax purposes and does not signal a change in the company's fundamentals or management's confidence.

Key Dates

Keywords

Akero Therapeutics, AKRO, Timothy Rolph, Chief Scientific Officer, Insider Transaction, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, Sell-to-Cover, 10b5-1 Plan